Barcode Alzheimer Biomarkers with Barcoded Magnetic Beads

描述（由申请人提供）：条形码阿尔茨海默氏症生物标志物与条形码磁珠摘要：目前的诊断阿尔茨海默氏症在很大程度上依赖于记录智力下降。tau和Ab 42已被证明可用于预测患有非常轻度痴呆或轻度认知障碍的个体的临床进展。然而，即使对于这些分析物，对照组和AD组之间也存在大量重叠，并且需要更好的预后能力。鉴于AD病理生理学的多因素性质，很可能 在这方面还有其它有用的生物标志物。阿尔茨海默病神经影像学倡议（ADNI）使用靶向多重蛋白质组学策略来鉴定阿尔茨海默病（AD）中基于血浆的生物标志物。虽然蛋白质组学筛选已经鉴定了许多其他候选AD生物标志物，但很少有研究利用大的、充分表征的队列或在临床前或非常早期的疾病中寻找生物标志物。虽然已经做了大量的工作，不幸的是，从大量的蛋白质谱中寻找生物标志物仍然是一个艰巨的挑战。目前的方法存在劳动强度大、成本高、灵敏度差、变异系数大等缺点.此外，研究人员始终面临的一个挑战是，同一样本中的蛋白质水平分析往往因机构而异。目前基于多重免疫分析的生物标志物发现技术主要有：1.微阵列生物芯片：它具有差的机械点样重复性，没有内容物（目标添加）灵活性，反应动力学差，灵敏度低，并且不能定量。2.基于微珠的流式细胞仪：它不是定量的，具有较大的CV（15%-30%），有限的灵敏度，beas结转，目前每个面板仅覆盖有限的分析物。Applied BioCode，Inc.提出用条形码磁珠（AD-BMB）对所有潜在的阿尔茨海默病生物标志物进行条形码化，这将为一合一或多合一生物标志物筛选和鉴定提供“高多样性”、“高灵敏度”和“高准确性”。条形码磁珠（BMB）利用数字技术而不是传统的模拟方法，提供无与伦比的多路复用能力，内容灵活性，解码精度和出色的灵敏度。更重要的是，该分析仪易于使用，坚固耐用，并将提供一致的， 准确的结果。专家认为，生物标志物提供了一个最有前途的路径作为可靠的预测和阿尔茨海默病的指标。 公共卫生相关性：由此产生的AD-BMB技术将提供有效的、具有成本效益的、基于脑脊液（CSF）或血浆的多重测定平台来鉴定阿尔茨海默病生物标志物，使其成为作为AD的预测因子和指标的有效诊断工具。 除了阿尔茨海默氏症的应用，AD-BMB技术在生物医学和生物科学研究领域有着广泛的应用。

DESCRIPTION (provided by applicant): Barcode Alzheimer Biomarkers with Barcoded Magnetic Beads Abstract: Current diagnosis of Alzheimer's relies largely on documenting mental decline. The tau and Ab42 have proven useful for predicting clinical progression in individuals who have very mild dementia or mild cognitive impairment. Nevertheless, even for these analytes, there is substantial overlap between control and AD groups, and a need for better prognostic ability. Given the multifactorial nature of AD pathophysiology, it is likely that there will be other biomarkers that will be useful in this regard. Alzheimer's Disease Neuroimaging Initiative (ADNI) uses targeted multiplex proteomic strategies to identify plasma-based biomarkers in Alzheimer's Disease (AD). While proteomic screens have identified a number of other candidate AD biomarkers, few studies have utilized large, well-characterized cohorts or have looked for biomarkers in preclinical or very early stage disease. While a great deal of works has been done, unfortunately, searching for biomarkers from a large number of protein profiling is still a daunting challenge. The current methods are labor intensive, high cost poor sensitivity, and have large CV. Moreover, one challenge researchers always face is that analysis of protein levels in the same sample often varies significantly from institution to institution. Current biomarker discovery technologies based on multiplex immunoassay are: 1. Microarray biochip: It has poor mechanical spotting repeatability, no content (target add-on) flexibility, poor reaction kinetics, low sensitivity, and not quantitative. 2. Bead based flow cytometer: It is not quantitative, has large CV (15 percent - 30 percent), limited sensitivity, beas carried over, and currently each panel only cover limited analytes. Applied BioCode, Inc. proposes to barcode all potential Alzheimer Disease Biomarkers with Barcoded Magnetic Beads (AD-BMB), which will provide the "high multiplicity", "high sensitivity", and "high accuracy" for al-in-one or many-in-one biomarkers screening and identification. Barcoded Magnetic Beads (BMB) utilize digital technology instead of conventional analog methodology, offering unmatched multiplexing capability, content flexibility, decoding accuracy and excellent sensitivity. More importantly, the analyzer is easy to use, robust, and will provide consistent and accurate results. Experts believe that biomarkers offer one of the most promising paths as reliable predictors and indicators of Alzheimer disease. PUBLIC HEALTH RELEVANCE: The resulting AD-BMB technology will offer an efficient, cost-effective, cerebrospinal fluid (CSF) or plasma- based multiplex assay platform to identify Alzheimer biomarkers, making it a potent diagnostic tool as predictors and indicators of AD. In addition to the Alzheimer application, the AD-BMB technology has a wide variety of applications in the biomedical and bioscience research fields.